Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Exact Sciences Corporation showcased substantial growth and improved profitability throughout 2023.</li><li>With a 24% increase in core revenue amounting to $2.5 billion and an uplifted adjusted EBITDA amounting to $362 million, the firm grew robustly.</li><li>This success is largely credited to the advancement of its mission to eradicate cancer via the facilitation of innovative screening and precision oncology under major brands like Cologuard, Oncotype DX, and PreventionGenetics.</li></ul>

Exact Sciences Corporation showcased substantial growth and improved profitability throughout 2023.With a 24% increase in core revenue amounting to $2.5 billion and an uplifted adjusted EBITDA amounting to $362 million, the firm grew robustly.This success is largely credited to the advancement of its mission to eradicate cancer via the facilitation of innovative screening and precision oncology under major brands like Cologuard, Oncotype DX, and PreventionGenetics.

Exact Sciences Corporation: Launch Of MRD product OncoDetect & Other New Products! - Major Drivers

<ul><li>Exact Sciences Corporation delivered a positive result and managed an all-around beat in the quarter.</li><li>During the quarter, over 10,000 new healthcare professionals ordered Cologuard, contributing to a total of more than 331,000 orders since its launch.</li><li>Looking ahead, Exact Sciences raised its total revenue guidance for the year to a range of $2.476 billion to $2.486 billion.</li></ul>

Exact Sciences Corporation delivered a positive result and managed an all-around beat in the quarter.During the quarter, over 10,000 new healthcare professionals ordered Cologuard, contributing to a total of more than 331,000 orders since its launch.Looking ahead, Exact Sciences raised its total revenue guidance for the year to a range of $2.476 billion to $2.486 billion.

Exact Sciences Corporation: Cologuard Market Positioning & Long-Term Growth Strategy! - Major Drivers

<ul><li>Exact Sciences Corporation exceeded Wall Street's revenue and earnings expectations.</li><li>Revenue increased in the second quarter.</li><li>Exact Sciences continues to see widespread Cologuard acceptance and traction among health systems.</li></ul>

Exact Sciences Corporation exceeded Wall Street's revenue and earnings expectations.Revenue increased in the second quarter.Exact Sciences continues to see widespread Cologuard acceptance and traction among health systems.

Exact Sciences Corporation: Cancer Research Through Collaborative Partnerships & Other Drivers

<ul><li>EXACT Sciences delivered an all-around beat in the previous quarter.</li><li>Core revenue grew and screening revenue increased.</li><li>Gross margin furthered from the fixed cost leverage in EXACT Sciences' lab, the Cologuard patient compliance program, and the billing systems.</li></ul>

EXACT Sciences delivered an all-around beat in the previous quarter.Core revenue grew and screening revenue increased.Gross margin furthered from the fixed cost leverage in EXACT Sciences' lab, the Cologuard patient compliance program, and the billing systems.

EXACT Sciences Corporation: Pipeline Advancements & Cologuard Adoption Catalyzing Its Growth? – Key Drivers

Fundamental Short Selling Research

Eric Fernandez, CFA

TwoRiversAnalytics

<ul>
<li>Liquidity shorts can be great short candidates.  The key characteristic is that the company may not be viable, economically, given their cash flows and cash requirements. </li>
<li>Liquidity shorts have built-in catalysts, have moderate to higher betas,  and can have strong down moves if a crisis develops.  They can go bankrupt, pushing the stock price near zero.</li>
<li>Today we are flagging Carvana, Exact Sciences, Inspire Med, Freshpet, Enviva .</li>
</ul>


Liquidity shorts can be great short candidates.  The key characteristic is that the company may not be viable, economically, given their cash flows and cash requirements. 
Liquidity shorts have built-in catalysts, have moderate to higher betas,  and can have strong down moves if a crisis develops.  They can go bankrupt, pushing the stock price near zero.
Today we are flagging Carvana, Exact Sciences, Inspire Med, Freshpet, Enviva .


Liquidity Risk Short Candidates: Carvana, Exact Sciences, Inspire Med, Freshpet, Enviva

United States

Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Exact Sciences (EXAS US)

Exact Sciences Corporation: Launch Of MRD product OncoDetect & Other New Products! - Major Drivers

Exact Sciences Corporation showcased substantial growth and improved profitability throughout 2023. With a 24% increase in core revenue amounting...

Baptista Research

Exact Sciences Corporation: Cologuard Market Positioning & Long-Term Growth Strategy! - Major Drivers

Exact Sciences Corporation delivered a positive result and managed an all-around beat in the quarter. During the quarter, over 10,000 new...

Baptista Research

Exact Sciences Corporation: Cancer Research Through Collaborative Partnerships & Other Drivers

Exact Sciences Corporation exceeded Wall Street's revenue and earnings expectations. Revenue increased in the second quarter. Exact Sciences...

Baptista Research

EXACT Sciences Corporation: Pipeline Advancements & Cologuard Adoption Catalyzing Its Growth? – Key Drivers

EXACT Sciences delivered an all-around beat in the previous quarter. Core revenue grew and screening revenue increased. Gross margin furthered...

Baptista Research

Liquidity Risk Short Candidates: Carvana, Exact Sciences, Inspire Med, Freshpet, Enviva

Liquidity risk short candidates may not be economically viable given cash flows and capital requirements. This week we flag Carvana, Exact...

Eric Fernandez, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)